In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86521
Title:
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Authors:
Kottaridis, Panagiotis D; Milligan, Donald W; Chopra, Rajesh; Chakraverty, Ronjon; Chakrabarti, Suparno; Robinson, Stephen P; Peggs, Karl S; Verfuerth, Stephanie; Pettengell, Ruth; Marsh, Judith C W; Schey, Stephen; Mahendra, Premini; Morgan, Gareth J; Hale, Geoff; Waldmann, Herman; De Elvira, M Carmen Ruiz; Williams, Catherine D; Devereux, Stephen; Linch, David C; Goldstone, Anthony H; Mackinnon, Stephen
Abstract:
A novel nonmyeloablative conditioning regimen was investigated in 44 patients with hematologic malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. Recipient conditioning consisted of CAMPATH-1H, 20 mg/day on days -8 to -4; fludarabine, 30 mg/m(2) on days -7 to -3; and melphalan, 140 mg/m(2) on day -2. Thirty-six recipients received unmanipulated granculocyte colony-stimulating factor-mobilized peripheral blood stem cells from HLA-identical siblings, and 8 received unmanipulated marrow from matched unrelated donors. GVHD prophylaxis was with cyclosporine A alone for 38 patients and cyclosporine A plus methotrexate for 6 sibling recipients. Forty-two of the 43 evaluable patients had sustained engraftment. Results of chimerism analysis using microsatellite polymerase chain reaction indicate that 18 of 31 patients studied were full-donor chimeras while the other patients were mixed chimeras in one or more lineages. At a median follow-up of 9 months (range 3 to 29 months), 33 patients remain alive in complete remission or with no evidence of disease progression. Seven patients relapsed or progressed post-transplantation, and 4 of them subsequently died. Four patients died of regimen-related complications. There were no cases of grades III-IV acute GVHD. Only 2 patients developed grade II acute GVHD, and only 1 had chronic GVHD. The estimated probability of nonrelapse mortality was 11%. Although longer follow-up is needed to establish the long-term remission rates, this study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity, and low incidence of GVHD.
Affiliation:
Departments of Hematology, University College London Hospital, London, England.
Citation:
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. 2000, 96 (7):2419-25 Blood
Journal:
Blood
Issue Date:
1-Oct-2000
URI:
http://hdl.handle.net/10541/86521
PubMed ID:
11001893
Type:
Article
Language:
en
ISSN:
0006-4971
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorKottaridis, Panagiotis Den
dc.contributor.authorMilligan, Donald Wen
dc.contributor.authorChopra, Rajeshen
dc.contributor.authorChakraverty, Ronjonen
dc.contributor.authorChakrabarti, Suparnoen
dc.contributor.authorRobinson, Stephen Pen
dc.contributor.authorPeggs, Karl Sen
dc.contributor.authorVerfuerth, Stephanieen
dc.contributor.authorPettengell, Ruthen
dc.contributor.authorMarsh, Judith C Wen
dc.contributor.authorSchey, Stephenen
dc.contributor.authorMahendra, Preminien
dc.contributor.authorMorgan, Gareth Jen
dc.contributor.authorHale, Geoffen
dc.contributor.authorWaldmann, Hermanen
dc.contributor.authorDe Elvira, M Carmen Ruizen
dc.contributor.authorWilliams, Catherine Den
dc.contributor.authorDevereux, Stephenen
dc.contributor.authorLinch, David Cen
dc.contributor.authorGoldstone, Anthony Hen
dc.contributor.authorMackinnon, Stephenen
dc.date.accessioned2009-11-19T16:52:44Z-
dc.date.available2009-11-19T16:52:44Z-
dc.date.issued2000-10-01-
dc.identifier.citationIn vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. 2000, 96 (7):2419-25 Blooden
dc.identifier.issn0006-4971-
dc.identifier.pmid11001893-
dc.identifier.urihttp://hdl.handle.net/10541/86521-
dc.description.abstractA novel nonmyeloablative conditioning regimen was investigated in 44 patients with hematologic malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. Recipient conditioning consisted of CAMPATH-1H, 20 mg/day on days -8 to -4; fludarabine, 30 mg/m(2) on days -7 to -3; and melphalan, 140 mg/m(2) on day -2. Thirty-six recipients received unmanipulated granculocyte colony-stimulating factor-mobilized peripheral blood stem cells from HLA-identical siblings, and 8 received unmanipulated marrow from matched unrelated donors. GVHD prophylaxis was with cyclosporine A alone for 38 patients and cyclosporine A plus methotrexate for 6 sibling recipients. Forty-two of the 43 evaluable patients had sustained engraftment. Results of chimerism analysis using microsatellite polymerase chain reaction indicate that 18 of 31 patients studied were full-donor chimeras while the other patients were mixed chimeras in one or more lineages. At a median follow-up of 9 months (range 3 to 29 months), 33 patients remain alive in complete remission or with no evidence of disease progression. Seven patients relapsed or progressed post-transplantation, and 4 of them subsequently died. Four patients died of regimen-related complications. There were no cases of grades III-IV acute GVHD. Only 2 patients developed grade II acute GVHD, and only 1 had chronic GVHD. The estimated probability of nonrelapse mortality was 11%. Although longer follow-up is needed to establish the long-term remission rates, this study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity, and low incidence of GVHD.en
dc.language.isoenen
dc.subjectHaematologic Canceren
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntibodies, Neoplasm-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshCyclosporine-
dc.subject.meshDrug Therapy, Combination-
dc.subject.meshFemale-
dc.subject.meshGraft vs Host Disease-
dc.subject.meshGranulocyte Colony-Stimulating Factor-
dc.subject.meshHematologic Neoplasms-
dc.subject.meshHematopoietic Stem Cell Transplantation-
dc.subject.meshHistocompatibility Testing-
dc.subject.meshHumans-
dc.subject.meshImmunosuppressive Agents-
dc.subject.meshMale-
dc.subject.meshMelphalan-
dc.subject.meshMethotrexate-
dc.subject.meshMicrosatellite Repeats-
dc.subject.meshMiddle Aged-
dc.subject.meshNuclear Family-
dc.subject.meshPolymerase Chain Reaction-
dc.subject.meshRecurrence-
dc.subject.meshTransplantation Chimera-
dc.subject.meshTransplantation Conditioning-
dc.subject.meshTreatment Outcome-
dc.subject.meshVidarabine-
dc.titleIn vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.en
dc.typeArticleen
dc.contributor.departmentDepartments of Hematology, University College London Hospital, London, England.en
dc.identifier.journalBlooden

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.